MTOR and cancer: To test the hypothesis that HAR and PIP sensitize cells that are resistant to anti-cancer drugs, we first sought to determine the most effective concentrations for combined treatment with the PI3K/mTOR inhibitor BEZ235 and HAR or PIP.